June 18, 2007 - Researchers at the University of Pennsylvania have created the first three-dimensional optical images of human breast cancer in patients based on tissue fluorescence which relies on the presence of fluorophore molecules in tissue that re-radiate fluorescent light after illumination by excitation light of a different color.

The reconstructed images demonstrated significant tumor contrast compared to typical endogenous optical contrast in breast. Tumor-to-normal tissue contrast based on fluorescence diffuse optical tomography, or FDOT with the fluorophore Indocyanine Green, or ICG, was two-to-four-fold higher than contrast based on endogenous contrasts such as hemoglobin and scattering parameters obtained with traditional diffuse optical tomography, or DOT.

With the continued development of molecularly-targeted exogenous fluorophores, the research helps pave the way for diagnostic tools based on optics that will provide improved sensitivity and specificity between healthy and normal tissues.

Fluorophores are exquisitely sensitive to their local environment and therefore FDOT holds potential to provide information about tumor physiology, including tissue oxygen, tissue pH and tissue calcium concentration levels.

For more information: www.upenn.edu


Related Content

News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Breast Imaging

April 1, 2026 — QT Imaging Holdings has released its latest image reconstruction software update, version 4.5.0. This ...

Time April 02, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Breast Imaging

March 30, 2026 — Each year, the Alumni Association at the University of Missouri-Kansas City, recognizes the ...

Time March 31, 2026
arrow
News | MRI Breast | Breast cancer, dense breast, MRI

March 2, 2026 — A collaborative modeling study found that adding biennial breast magnetic resonance imaging (MRI) to ...

Time March 20, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
Subscribe Now